Denosumab Promising for TDT-Induced Osteoporosis Treatment

TUESDAY, Nov. 13, 2018 -- Denosumab (DNM), a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), may be beneficial for managing transfusion-dependent thalassemia (TDT)-induced osteoporosis,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news